These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 30382908)

  • 41. Impact of Cellular Genetic Make-up on Colorectal Cancer Cell Lines Response to Ellagic Acid: Implications of Small Interfering RNA.
    Yousef AI; El-Masry OS; Abdel Mohsen MA
    Asian Pac J Cancer Prev; 2016; 17(2):743-8. PubMed ID: 26925673
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.
    Zhang Y; Yao K; Shi C; Jiang Y; Liu K; Zhao S; Chen H; Reddy K; Zhang C; Chang X; Ryu J; Bode AM; Dong Z; Dong Z
    Oncotarget; 2015 Dec; 6(42):44274-88. PubMed ID: 26517520
    [TBL] [Abstract][Full Text] [Related]  

  • 43. NG25, a novel inhibitor of TAK1, suppresses KRAS-mutant colorectal cancer growth in vitro and in vivo.
    Ma Q; Gu L; Liao S; Zheng Y; Zhang S; Cao Y; Zhang J; Wang Y
    Apoptosis; 2019 Feb; 24(1-2):83-94. PubMed ID: 30515612
    [TBL] [Abstract][Full Text] [Related]  

  • 44.
    Seo H; Song J; Kim M; Han DW; Park HJ; Song M
    Nutrients; 2018 Dec; 11(1):. PubMed ID: 30577618
    [No Abstract]   [Full Text] [Related]  

  • 45. KARATE: PKA-induced KRAS4B-RHOA-mTORC2 supercomplex phosphorylates AKT in insulin signaling and glucose homeostasis.
    Senoo H; Murata D; Wai M; Arai K; Iwata W; Sesaki H; Iijima M
    Mol Cell; 2021 Nov; 81(22):4622-4634.e8. PubMed ID: 34551282
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lycorine inhibits cell proliferation, migration and invasion, and primarily exerts
    Zhang P; Yuan X; Yu T; Huang H; Yang C; Zhang L; Yang S; Luo X; Luo J
    Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649853
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Wentilactone A as a novel potential antitumor agent induces apoptosis and G2/M arrest of human lung carcinoma cells, and is mediated by HRas-GTP accumulation to excessively activate the Ras/Raf/ERK/p53-p21 pathway.
    Lv C; Hong Y; Miao L; Li C; Xu G; Wei S; Wang B; Huang C; Jiao B
    Cell Death Dis; 2013 Dec; 4(12):e952. PubMed ID: 24309939
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Farnesylated and methylated KRAS4b: high yield production of protein suitable for biophysical studies of prenylated protein-lipid interactions.
    Gillette WK; Esposito D; Abreu Blanco M; Alexander P; Bindu L; Bittner C; Chertov O; Frank PH; Grose C; Jones JE; Meng Z; Perkins S; Van Q; Ghirlando R; Fivash M; Nissley DV; McCormick F; Holderfield M; Stephen AG
    Sci Rep; 2015 Nov; 5():15916. PubMed ID: 26522388
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells.
    Song Q; Sun X; Guo H; Yu Q
    Oncotarget; 2017 Jan; 8(3):5003-5015. PubMed ID: 28002807
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tunicamycin inhibits colon carcinoma growth and aggressiveness via modulation of the ERK-JNK-mediated AKT/mTOR signaling pathway.
    You S; Li W; Guan Y
    Mol Med Rep; 2018 Mar; 17(3):4203-4212. PubMed ID: 29344654
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Resistance to 3-HTMC-Induced Apoptosis Through Activation of PI3K/Akt, MEK/ERK, and p38/COX-2/PGE
    Semaan J; Pinon A; Rioux B; Hassan L; Limami Y; Pouget C; Fagnère C; Sol V; Diab-Assaf M; Simon A; Liagre B
    J Cell Biochem; 2016 Dec; 117(12):2875-2885. PubMed ID: 27192488
    [TBL] [Abstract][Full Text] [Related]  

  • 52. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
    Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
    Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
    J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Synthetic Lethality of a Novel Small Molecule Against Mutant KRAS-Expressing Cancer Cells Involves AKT-Dependent ROS Production.
    Iskandar K; Rezlan M; Yadav SK; Foo CH; Sethi G; Qiang Y; Bellot GL; Pervaiz S
    Antioxid Redox Signal; 2016 May; 24(14):781-94. PubMed ID: 26714745
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The inhibitory effect of doxycycline on cisplatin-sensitive and -resistant epithelial ovarian cancer.
    Wu W; Yu LH; Ma B; Xu MJ
    PLoS One; 2014; 9(3):e89841. PubMed ID: 24598933
    [TBL] [Abstract][Full Text] [Related]  

  • 56. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
    Wong CC; Qian Y; Li X; Xu J; Kang W; Tong JH; To KF; Jin Y; Li W; Chen H; Go MY; Wu JL; Cheng KW; Ng SS; Sung JJ; Cai Z; Yu J
    Gastroenterology; 2016 Nov; 151(5):945-960.e6. PubMed ID: 27451147
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer.
    Agarwal E; Chaudhuri A; Leiphrakpam PD; Haferbier KL; Brattain MG; Chowdhury S
    BMC Cancer; 2014 Mar; 14():145. PubMed ID: 24581231
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A small molecule inhibits Akt through direct binding to Akt and preventing Akt membrane translocation.
    Kim D; Sun M; He L; Zhou QH; Chen J; Sun XM; Bepler G; Sebti SM; Cheng JQ
    J Biol Chem; 2010 Mar; 285(11):8383-94. PubMed ID: 20068047
    [TBL] [Abstract][Full Text] [Related]  

  • 59. LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo.
    Zhou J; Zheng B; Ji J; Shen F; Min H; Liu B; Wu J; Zhang S
    Tumour Biol; 2015 May; 36(5):3301-8. PubMed ID: 25524577
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
    García-García C; Rivas MA; Ibrahim YH; Calvo MT; Gris-Oliver A; Rodríguez O; Grueso J; Antón P; Guzmán M; Aura C; Nuciforo P; Jessen K; Argilés G; Dienstmann R; Bertotti A; Trusolino L; Matito J; Vivancos A; Chicote I; Palmer HG; Tabernero J; Scaltriti M; Baselga J; Serra V
    Clin Cancer Res; 2015 Dec; 21(24):5499-5510. PubMed ID: 26272063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.